| ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer R Jeselsohn, G Buchwalter, C De Angelis, M Brown, R Schiff Nature reviews Clinical oncology 12 (10), 573, 2015 | 327 | 2015 |
| Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up L Malorni, PB Shetty, C De Angelis, S Hilsenbeck, MF Rimawi, R Elledge, ... Breast cancer research and treatment 136 (3), 795-804, 2012 | 117 | 2012 |
| FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer X Fu, R Jeselsohn, R Pereira, EF Hollingsworth, CJ Creighton, F Li, ... Proceedings of the National Academy of Sciences 113 (43), E6600-E6609, 2016 | 83 | 2016 |
| The changing role of ER in endocrine resistance A Nardone, C De Angelis, MV Trivedi, CK Osborne, R Schiff The Breast 24, S60-S66, 2015 | 75 | 2015 |
| Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer G Arpino, C De Angelis, M Giuliano, A Giordano, C Falato, ... Oncology 77 (Suppl. 1), 23-37, 2009 | 69 | 2009 |
| The evolving role of the estrogen receptor mutations in endocrine therapy-resistant breast cancer R Jeselsohn, C De Angelis, M Brown, R Schiff Current oncology reports 19 (5), 35, 2017 | 67 | 2017 |
| Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy M Giuliano, H Hu, YC Wang, X Fu, A Nardone, S Herrera, S Mao, ... Clinical Cancer Research 21 (17), 3995-4003, 2015 | 60 | 2015 |
| Embryonic transcription factor SOX9 drives breast cancer endocrine resistance R Jeselsohn, MI Cornwell, M Pun, G Buchwalter, M Nguyen, C Bango, ... Proceedings of the National Academy of Sciences 114 (22), E4482-E4491, 2017 | 58 | 2017 |
| HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2+ breast cancer X Xu, C De Angelis, KA Burke, A Nardone, H Hu, L Qin, J Veeraraghavan, ... Clinical Cancer Research 23 (17), 5123-5134, 2017 | 55 | 2017 |
| Overcoming Treatment Resistance in HER2-Positive Breast Cancer F Puglisi, AM Minisini, C De Angelis, G Arpino Drugs 72 (9), 1175-1193, 2012 | 48 | 2012 |
| Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2–ERα–GREB1 Transcriptional Axis Y Wu, Z Zhang, ME Cenciarini, CJ Proietti, M Amasino, T Hong, M Yang, ... Cancer research 78 (3), 671-684, 2018 | 46 | 2018 |
| Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer MF Rimawi, C De Angelis, A Contreras, F Pareja, FC Geyer, KA Burke, ... Breast cancer research and treatment 167 (3), 731-740, 2018 | 42 | 2018 |
| Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis M Bonotto, L Gerratana, M Di Maio, C De Angelis, M Cinausero, S Moroso, ... The Breast 31, 114-120, 2017 | 42 | 2017 |
| De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance J Veeraraghavan, C De Angelis, JS Reis-Filho, T Pascual, A Prat, ... The Breast 34, S19-S26, 2017 | 36 | 2017 |
| HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade A Prat, T Pascual, C De Angelis, C Gutierrez, A Llombart-Cussac, T Wang, ... JNCI: Journal of the National Cancer Institute 112 (1), 46-54, 2020 | 33 | 2020 |
| Towards personalized treatment for early stage HER2-positive breast cancer K Goutsouliak, J Veeraraghavan, V Sethunath, C De Angelis, CK Osborne, ... Nature Reviews Clinical Oncology 17 (4), 233-250, 2020 | 32 | 2020 |
| Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy G Arpino, C De Angelis, G Buono, A Colao, M Giuliano, S Malgieri, ... Breast cancer research and treatment 154 (1), 127-132, 2015 | 31 | 2015 |
| Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial S De Placido, C Gallo, M De Laurentiis, G Bisagni, G Arpino, MG Sarobba, ... The lancet oncology 19 (4), 474-485, 2018 | 30 | 2018 |
| Blockade of AP-1 potentiates endocrine therapy and overcomes resistance L Malorni, M Giuliano, I Migliaccio, T Wang, CJ Creighton, M Lupien, X Fu, ... Molecular Cancer Research 14 (5), 470-481, 2016 | 27 | 2016 |
| FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer X Fu, R Pereira, C De Angelis, J Veeraraghavan, S Nanda, L Qin, ... Proceedings of the National Academy of Sciences 116 (52), 26823-26834, 2019 | 24 | 2019 |
Rachel SchiffBaylor College of MedicineVerified email at bcm.edu
